You are here: Industry Insights > ASCO

News List

Latest Data of InnoCare’s Robust Oncology Pipelines Presented at the 2022 ASCO Annual Meeting PharmaSources.com
June 07, 2022
Latest data of InnoCare’s robust oncology pipeline were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
Potential new CAR-T cell therapy for multiple myeloma firstwordpharma
June 28, 2021
Researchers at Mayo Clinic Cancer Center are studying a potential new chimeric antigen receptor-T cell therapy (CAR-T cell therapy) treatment for multiple myeloma. Their findings were published on Friday, June 24, in The Lancet.
SOTIO Presents Positive Biomarker Data from DCVAC/OvCa Phase 2 Study in First Line Ovarian Cancer at the 2021 ASCO Annual Meeting b3cnewswire
June 07, 2021
SOTIO today announced the presentation of positive biomarker data from its Phase 2 trial with dendritic cell vaccine DCVAC/OvCa during a virtual poster presentation at the 2021 ASCO Annual Meeting.
Yingli Pharma Announces presentations on the Phase 1 trials of linperlisib, a PI3Kδ selective inhibitor, and YL-13027, an oral TGFβR1 inhibitor, at the American Society for Clinical Oncology 2021 Annu prnasia
June 04, 2021
Shanghai Yingli Pharmaceuticals Ltd announced today that there will be three presentations on clinical trials sponsored by the company at the annual meeting of the American Society for Clinical Oncology (ASCO) June 4-7, 2021.
ImmVira will present the U.S. Clinical Phase I Study Results of MVR-T3011 via Intratumoral Administration at ASCO 2021 prnasia
June 03, 2021
ImmVira will present results from its clinical Phase I study of MVR-T3011 via intratumoral (IT) administration at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting on June 4-8, 2021 for the first time.
Eucure Biopharma to Present Findings From Anti-CD40 and Anti-CTLA-4 mAb Clinical Trials at the 2021 ASCO Meeting prnasia
June 02, 2021
Eucure Biopharma will present findings from two Phase I clinical trials at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held from June 4th to 8th.
Janssen’s Phase 1 Results for Teclistamab Suggest Deep, Durable Responses americanpharmaceuticalreview
May 28, 2021
Subcutaneous administration of BCMAxCD3 T-cell redirecting bispecific antibody demonstrated clinical activity and a manageable safety profile according to new data at ASCO.
HPV Vaccination Is Lowering U.S. Cervical Cancer Rates drugs
May 20, 2021
In a finding that offers the first evidence that the human papillomavirus (HPV) vaccine is indeed protecting women from cervical cancer, new research shows cases in the United States have slowly but steadily declined over the last decade and a half.
Clovis Oncology Highlights Rubraca (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting firstwordpharma
May 20, 2021
Clovis Oncology, today announced that four abstracts featuring data will be presented during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually, June 4-8, 2021.
ImmVira Announces Preclinical and Clinical Data to Be Presented at the 2021 ASCO and AACR Annual Meeting prnasia
April 09, 2021
ImmVira announces that the company will be presenting its first innovative product, MVR-T3011, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting on June 4-8 2021.

Previous page 1 2 3 4 Next page